We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) Stelara Gets Approval in EU for Label Expansion
Read MoreHide Full Article
Johnson & Johnson’s (JNJ - Free Report) subsidiary, Janssen Therapeutics, announced that the European Commission (EC) has approved its prescription drug Stelara for the treatment of moderate-to-severely active Crohn’s disease in adults.
Stelara is presently marked in the EU and U.S. for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.
The approval was not surprising as the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had granted a positive opinion to Stelara, recommending approval for the indication in September. Also, in the same month, Stelara received the FDA approval for the same indication. J&J is also evaluating Stelara as a subcutaneous treatment for ulcerative colitis (phase III ongoing) and axial spondylytis (phase III).
Sales of Stelara in the upcoming quarters should receive a boost with this label expansion. According to the company’s press release, more than five million people worldwide suffer from Crohn’s disease and ulcerative colitis which are collectively referred to as inflammatory bowel disease (IBD).
Apart from Stelara, J&J is also working actively on expanding the label of other new marketed products like Simponi, Xarelto and Imbruvica. For Imbruvica (partner: AbbVie, Inc. (ABBV - Free Report) , six additional indications have been approved since its launch and the drug is also being evaluated in a number of combination therapies. For Xarelto, there are eight new indications seeking trials as part of the EXPLORER clinical development program. While Johnson & Johnson has exclusive U.S. marketing rights of Xarelto, the drug is being marketed by Bayer AG (BAYRY - Free Report) outside the U.S.
Simponi (partner: Merck & Co., Inc. (MRK - Free Report) received approval this year in the EU for the treatment of polyarticular juvenile idiopathic arthritis in combination with methotrexate. Also, the company plans to file two line extensions for Simponi Aria, the intravenous formulation of Simponi, in psoriatic arthritis and ankylosing spondylitis. We believe that in the forthcoming period, these drugs will contribute significantly to the company’s top line.
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
J&J (JNJ) Stelara Gets Approval in EU for Label Expansion
Johnson & Johnson’s (JNJ - Free Report) subsidiary, Janssen Therapeutics, announced that the European Commission (EC) has approved its prescription drug Stelara for the treatment of moderate-to-severely active Crohn’s disease in adults.
Stelara is presently marked in the EU and U.S. for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.
The approval was not surprising as the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had granted a positive opinion to Stelara, recommending approval for the indication in September. Also, in the same month, Stelara received the FDA approval for the same indication. J&J is also evaluating Stelara as a subcutaneous treatment for ulcerative colitis (phase III ongoing) and axial spondylytis (phase III).
Sales of Stelara in the upcoming quarters should receive a boost with this label expansion. According to the company’s press release, more than five million people worldwide suffer from Crohn’s disease and ulcerative colitis which are collectively referred to as inflammatory bowel disease (IBD).
JOHNSON & JOHNS Price and Consensus
JOHNSON & JOHNS Price and Consensus | JOHNSON & JOHNS Quote
Apart from Stelara, J&J is also working actively on expanding the label of other new marketed products like Simponi, Xarelto and Imbruvica. For Imbruvica (partner: AbbVie, Inc. (ABBV - Free Report) , six additional indications have been approved since its launch and the drug is also being evaluated in a number of combination therapies. For Xarelto, there are eight new indications seeking trials as part of the EXPLORER clinical development program. While Johnson & Johnson has exclusive U.S. marketing rights of Xarelto, the drug is being marketed by Bayer AG (BAYRY - Free Report) outside the U.S.
Simponi (partner: Merck & Co., Inc. (MRK - Free Report) received approval this year in the EU for the treatment of polyarticular juvenile idiopathic arthritis in combination with methotrexate. Also, the company plans to file two line extensions for Simponi Aria, the intravenous formulation of Simponi, in psoriatic arthritis and ankylosing spondylitis. We believe that in the forthcoming period, these drugs will contribute significantly to the company’s top line.
J&J carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>